Survey of Ophthalmology
Volume 47 , Pages S2-S5 , August 2002

Changing Paradigms in the Medical Treatment of Glaucoma

  • Joern B Soltau, MD

      Affiliations

    • Corresponding Author InformationReprint address: Joern B. Soltau, MD, Kentucky Lions Eye Center, 301 East Muhammed Ali Boulevard, Louisville, KY 40202, USA
    • ,
  • Thom J Zimmerman, MD, PhD

References 

  1. The relationship between control of intraocular pressure and visual field deterioration. The Advanced Glaucoma Intervention Study (AGIS). Am J Ophthalmol. 2000;130:429–440
  2. Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor (Diamox). Am J Ophthalmol. 1954;37:13–17
  3. Berlin RJ, Lee UT, Samples JR. Ophthalmic drops causing coma in an infant. J Pediatr. 2001;138:441–443
  4. Butler P, Mannschreck M, Lin S. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol. 1995;113:293–296
  5. Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol. 2000;130:832–833
  6. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure. In the normal eye. Arch Ophthalmol. 1978;96:2045–2048
  7. Collaborative Normal-Tension Glaucoma Study Group . Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487–497
  8. Donohue EK, Wilensky JT. Dorzolamide (a review). Semin Ophthalmol. 1997;12:119–126
  9. Drance SM, Nash PA. The dose response of human intraocular pressure to pilocarpine. Can J Ophthalmol. 1971;6:9–13
  10. Fechtner RD. Initial medical management of open-angle glaucoma. J Glaucoma. 2000;9:83–86
  11. Fiscella RG, Geller JL, Gryz LL. Cost considerations of medical therapy for glaucoma. Am J Ophthalmol. 1999;128:426–433
  12. Haefliger IO, Pellanda N, Fleischhauer JC: [Neuroprotection in glaucoma. Where is the clinical evidence?] Ophthalmologe 98:564–7, 2001
  13. Hoyng PF, van Beek LM. Pharmacological therapy for glaucoma (a review). Drugs. 2000;59:411–434
  14. Kaufmann PL, Gabelt BT. Direct, indirect, and dual-action parasympathetic drugs. In:  Zimmerman TJ,  Kooner KS,  Sharir M,  Fechtner RD editor. Textbook of Ocular Pharmacology. Philadelphia: Lippincott-Raven; 1997;p. 221–238
  15. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol. 1991;111:51–55
  16. March WF, Ochsner KI. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. Am J Ophthalmol. 2000;129:136–143
  17. Maren TH. The rates of movements of NaCl and HCO3 from plasma to posterior chamber (effect of acetazolamide and relation to the treatment of glaucoma). Invest Ophthalmol. 1983;28(Suppl):280–284
  18. Martinez-Bello C, Chauhan BC, Nicolela MT. Intraocular pressure and progression of glaucomatous visual field loss. Am J Ophthalmol. 2000;129:302–308
  19. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179–191
  20. Schwartz M. Neuroprotection as a treatment for glaucoma (pharmacological and immunological approaches). Eur J Ophthalmol. 2001;11(Supp 2):S7–11
  21. Shirakashi M, Iwata K, Sawaguchi S. Intraocular pressure-dependent progression of visual field loss in advanced primary open-angle glaucoma (a 15-year follow-up). Ophthalmologica. 1993;207:1–5
  22. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514–1517
  23. Toris CB, Tafoya ME, Camras CB, Yablonski ME. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology. 1995;102:456–461
  24. Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology. 1980;87:447–450
  25. Vold SD, Wiggins DA, Jackimiec J. Cost analysis of glaucoma medications. J Glaucoma. 2000;9:150–153
  26. Zimmerman TJ, Fechtner RD. Maximal medical therapy for glaucoma. Arch Ophthalmol. 1997;115:1579–1580
  27. In:  Zimmerman TJ,  Kooner KS,  Sharir M,  Fechtner RD editor. Textbook of Ocular Pharmacology. Philadelphia, PA: Lippincott-Raven; 1997;

☆ Thom J. Zimmerman, MD, PhD, is a consultant and employee of Pharmacia Corp. The authors report no commercial or proprietary interest in any products mentioned or concepts discussed in this article.

PII: S0039-6257(02)00291-6

Survey of Ophthalmology
Volume 47 , Pages S2-S5 , August 2002

Article Tools